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esponsibility of InstAbstract Little attention has been paid to the effect of Rho-kinase inhibitor on the vascular
dysfunction of nitric oxide-deﬁcient hypertension. We aimed to investigate whether the Rho-kinase
inhibitor fasudil showed beneﬁcial effect on the vascular dysfunction of the NG-nitro-L-arginine
methyl ester (L-NAME) treated rat, as well as to compare the differential effects of fasudil and
angiotensin II receptor antagonist valsartan on vascular function. In the present study, both
valsartan and fasudil exerted antihypertensive action on the L-NAME-treated rats, while only
valsartan attenuated the cardiac hypertrophy. Treatment with valsartan showed improvement on
vascular reactivity to norepinephrine, KCl and CaCl2, whereas fasudil therapy showed little effect
on vasoconstriction. Endothelium-dependent vasodilation to acetylcholine was reduced in the NO-
deﬁcient group but was normalized by the fasudil therapy. The increased expression of RhoA and
Rho-kinase (ROCK) in the vasculature was corrected well to normal level by either valsartan or
fasudil administration, which seemed to be at least partially responsible for the beneﬁcial effect of
the drug infusion. These ﬁndings suggest that the angiotensin II receptor antagonist interferes moreedica, Chinese Academy of Medical Sciences and Chinese Pharmaceutical Association. Production and
rved.
.002
10 63165184.
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exhibits a better improvement on vasorelaxation than blockade of angiotensin II receptor.
& 2012 Institute of Materia Medica, Chinese Academy of Medical Sciences and Chinese Pharmaceutical
Association. Production and hosting by Elsevier B.V. All rights reserved.1. Introduction
Reduced production or activity of nitric oxide (NO) contri-
butes to several human diseases, especially hypertension1,2.
Therefore, NO-deﬁcient hypertension evoked by chronic
treatment with NO synthase (NOS) inhibitor NG-nitro-L-
arginine methyl ester (L-NAME) is a preferred animal model
for hypertension research3. This systemic hypertension may be
attributed to a deﬁciency in NO production by the vascula-
ture4. Previous reports have revealed the prevention of high
blood pressure and the improvement of vascular function in
NOS-blockaded animals through Ang II receptor antagonist
intervention5,6. Furthermore, valsartan has been reported to
decrease blood pressure and total peripheral resistance with
improved cardiac output in L-NAME-treated mice7. However,
little is known about the effect of Rho-kinase inhibitors on
this hypertension model.
Rho-kinase inhibitors target a wide range of human
ailments, including hypertension, heart failure, atherosclerosis,
diabetes, cerebral ischemia, glomerulosclerosis, Alzheimer’s
disease, bronchial asthma and cancers8,9. Fasudil, a selective
Rho-kinase inhibitor, is clinically used in China and Japan for
treating cerebral vasospasm after subarachnoid hemorrhage.
A dose-dependent vasorelaxative effect of fasudil has been
validated in humans based on the result of an increased blood
ﬂow and decreased resting vascular resistance in the forearm
after drug infusion10. However, there is no report about the
effect of fasudil on the vascular function of L-NAME-induced
hypertension. Thus, we aimed to investigate the beneﬁcial
potential of Rho-kinase inhibitor on the NO-deﬁcient hyper-
tensive rat and to compare the effects of Rho-kinase inhibitor
and AT1 blocker on the vascular function. The differential role
of fasudil and valsartan in the cardiac hypertrophy was also
addressed in the present study.2. Materials and methods
2.1. Animals and treatment
Male Wistar rats weighing 120–140 g were purchased from
Beijing Vital River Company, China, kept in polypropylene
cages (5 per cage) and housed in the institutional animal
facility with normal rodent chow and distilled water freely
available. All the procedures were in accordance with the
guidelines of the National Research Council and were
approved by the ethical committee of Chinese Academy of
Medical Sciences and Peking Union Medical College.
All the animals were suited in the environment mentioned
above for two weeks before the experiment. Then they were
randomly divided into two groups: control group (C, n¼15)
and L-NAME treated group (n¼54). Rats in the L-NAME
group received an intake of L-NAME (40 mg/kg, i.g.) everymorning and those in the control group received distilled
water intragastrically at the same time. Three weeks later,
systolic blood pressure (SBP) was measured by the tail-cuff
method (BP-98A, Softron, Japan) in two successive days, and
those with averaged SBPo140 mmHg in the L-NAME treated
group were excluded from the following study.
The rest animals in the L-NAME treated group were
randomly divided into three groups: model group (M,
n¼15), valsartan-treated group (V, n¼17) and fasudil-treated
group (F, n¼12). Rats in the groups C and M were orally
administrated with distilled water and L-NAME (40 mg/kg/
day), respectively. Rats in the group V were intragastrically
given L-NAME (40 mg/kg/day) plus valsartan, and those in
the group F were intragastrically given L-NAME (40 mg/kg/
day) plus fasudil. The doses of valsartan and fasudil were both
30 mg/kg/day. The treatments were carried out for 6 weeks
and stopped two or three days before the in vitro experiment in
order to avoid the effect of acute receptor occupancy11.
From the start of treatments, the SBP and heart rate of all
rats were determined weekly at 1 h after drug administration
by the tail-cuff instrument and were calculated as average
values of 3 measurements. The last SBP determination was
made before therapy was discontinued.2.2. Drugs and reagents
L-NAME, norepinephrine (NE), acetylcholine (Ach), Ang II
and phorbol dibutyrate (PDBu) were all purchased from
Sigma (Sigma Chemical Co., USA). Valsartan (Diovans,
Novartis) was commercially available and fasudil hydrochlor-
ide was kindly provided by Tianjin Chase Sun Pharmaceutical
Company (Tianjin, China). All other chemicals were of highest
grade available. Solutions used in the present study were all
prepared freshly and protected from light.2.3. Vessel preparation
Rats were weighed, anesthetized with urethane (1.0 g/kg, i.p.)
and killed by decapitation. The thoracic aorta was carefully
removed and placed in the cold Krebs–Henseleit (K–H) buffer
with the following composition (mM): NaCl 120, KCl 4.7,
KH2PO4 1.2, NaHCO3 25, glucose 11.1, CaCl2 2.5, MgSO4
1.2. The aortic rings (3 mm in length), cleaned of excess
connective tissue and fat, were mounted between two stainless
steel hooks in organ chambers containing 10 mL K–H solu-
tion (37 1C) with a gas mixture of 95% O2 and 5% CO2. One
of the two steel hooks was ﬁxed to the bottom of chambers,
and the other was connected to a force transducer in order to
record isometric tension (MP 100, BIOPAC, USA).
The rings were equilibrated at a resting tension of 1.2 g for
1 h. During the equilibration period, the K–H buffer was
replaced every 20 min, and the resting tension was readjusted.
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potassium K–H solution (80 mM), which was prepared by
replacing NaCl with KCl on an equimolar basis, were applied
to the aortas to record the maximum contractile response
to KCl.2.4. Vascular experimental protocols
The aortic rings were rinsed with K–H solution to return to
baseline tension after the response to high potassium K–H
solution. Then the cumulative dose-response curves of NE
(109–105 M) were registered on one of the two segments.
After a 20-min equilibration period, the aortic rings were
precontracted with 106 M NE followed by a concentration-
response to acetylcholine (109–104 M). The rings were
rinsed with K–H buffer twice and equilibrated in Ca2þ-free
K–H solution (containing 1 M EGTA) for another 20 min
with fresh Ca2þ-free solution replaced at 5-minute intervals. A
single dose of NE (106 M) was added into the organ bath to
obtain the transient contractile response to intracellular Ca2þ
released from the sarcoplasmic reticulum. Once the basal
tension value was restored, the rings were challenged with
80 M KCl in fresh Ca2þ-free K–H buffer followed by
cumulative addition of CaCl2 (0.1–2.5 mM).
KCl was added in a cumulative manner (10–80 mM) to another
segment of the aorta from each rat and the concentration–
response curve to KCl was registered. The rings were contracted
with a single concentration of Ang II (107 M) after a 20-min
washout period. Then the rings were rinsed with K–H solution
and allowed a recovery period for 20 min. To test the direct
relaxation of vascular smooth muscle, the vessels were precon-
tracted with 106 M NE followed by the cumulative addition of
sodium nitroprusside (1010–105 M) in the chambers. Thereafter,
responses to PDBu (107 M) were measured, and those rings were
allowed another 20-min equilibration period between the two
responses with the former vasodilator being washed away.2.5. Histological evaluation of heart
Excised hearts were ﬁxed with 10% neutral buffered formalin
before weighing at room temperature, and embedded in parafﬁn.
Coronal sections, 5 mm thick, were cut and mounted onto poly-L-
lysine coated slides. HE (hematoxylin and eosin) and Masson’s
trichrome staining was performed for different groups according
to the standard histochemical procedure. All histological sections
of each heart were examined using a color digital camera
(Canon, model EOS450D, Japan) mounted on a standard light
microscope (magniﬁcation 400). The transdiameters of 20
randomly selected cardiac myocytes from each sample stained
by HE were measured using the Image J software (National
Institute of Health, USA). To assess the area of interstitial
ﬁbrosis, a total of 15 ﬁelds per section stained by Masson’s
trichrome were evaluated using the Image-Pro Plus software
(Media Cybernetics, MD, USA), and the ratio of the total area
of ﬁbrosis to the total area of the image was calculated and used
for analysis. The histopathology was carried out by a researcher
who was blinded to the experimental groups.2.6. Western blot analysis of aorta
Aortas were removed from rats, immediately frozen in liquid
nitrogen and homogenized to obtain tissue protein samples.
Equal amounts of protein were loaded onto sodium dodecyl
sulfate polyacrylamide gels, and an electrophoresis was run at
100 V for 1.5 to 2 h (Bio-Rad, Hercules, CA, USA). Proteins
were then transferred to PVDF membranes (Millipore, USA).
The membranes were blocked with 5% bovine serum albumin
(BSA) in 0.1% Tween 20-phosphate-buffered saline for 4 h at
room temperature. Blots were probed with antibodies to
RhoA (Cell Signaling Technology, USA) or ROCK-I (Santa
Cruz Biotechnology, USA) at 4 1C overnight. Those blots
were then incubated with the appropriate horseradish perox-
idase-conjugated secondary antibody for 2 h at 37 1C. Between
steps, membranes were washed three times in tris/tween buffer.
Bound antibodies were detected by the ECL method (Mole-
cular Imager ChemiDoc XRSþ System, Bio-Rad, USA), and
the ﬁlms were analyzed by an imaging system (Quantity One
System, Bio-Rad, USA). Data were expressed as a fold of the
controls after normalization to GADPH expression.2.7. Statistical analysis
Contractions of the rat aorta were expressed as percentage of
the maximal contractile response to KCl (80 mM). Relaxa-
tions were expressed as percentage dilation of NE-induced
precontraction. In all series of experiments, n was the number
of rats from which the tissues were obtained. Results are given
as mean7SEM. All data were analyzed by one-way ANOVA
followed with the least signiﬁcant difference (LSD) test for
multiple comparisons. A two-tailed value of Po0.05 was
regarded as statistically signiﬁcant.3. Results
3.1. Blood pressure, heart rate and heart index
At the end of 3-week administration of L-NAME, the rats in
NO-deﬁciency developed sustained higher blood pressure
compared to the control rats, indicating an established
hypertensive state in those animals. As shown in Fig. 1, the
SBP and heart rate of rats in the control group remained at the
basal level during the 6-week treatment period; whereas the
blood pressure of rat in the model group displayed an
increase, reaching its maximum within 3 weeks. However,
the heart rate of the hypertensive rats was markedly lower
than the control rats. Both valsartan and fasudil treatment
effectively prevented the further rising of SBP (Fig. 1A).
Interestingly, valsartan treatment did not alter the heart rate,
but fasudil treatment signiﬁcantly increased the heart rate
compared to both the control and model groups (Fig. 1B).
After 6-week treatment, the body weights were similar in all
groups. The heart weights and heart-body weight ratios of the
model rats were much heavier and higher than those of the
control rats, while valsartan therapy reduced both of these
parameters signiﬁcantly. In contrast, fasudil treatment mark-
edly increased the heart weights and heart index (heart weight/
body weight) compared to the control group (Table 1).
Effects of Rho-kinase inhibitor and angiotensin II type-1 receptor antagonist on the hypertensive rats 4533.2. Vasoconstrictor-induced contractions
In aortic rings, the cumulative concentration–response to NE
(109–105 M) was markedly decreased in the L-NAME
induced hypertensive rats compared to the control rats
(Po0.05). Administration of valsartan signiﬁcantly improved
the aortic contraction evoked by NE, while fasudil treatment
corrected the defective constriction to some extent (Fig. 2A).
For the KCl- and CaCl2-induced contractile response, the
aorta of the model group showed slight reduction compared to
that of control group. However, there was no signiﬁcant
difference in all groups (Fig. 2B and C).
A single dose of Ang II and the protein kinase C activator
PDBu was added to the organ chamber resulting inFigure 1 Time course of SBP (A) and heart rate (B) during
6 weeks of treatment in control (K), model (’), valsartan-treated
(m) and fasudil-treated groups (.). Values are mean7SEM,
n¼12–17. Po0.05 compared with the control group, #Po0.05
compared with the model group.
Table 1 Body weight (BW), heart weight (HW) and heart weigh
BW (g)
Control 479710
Model 495711
Valsartan 490710
Fasudil 461715
Values are mean7SEM, n¼12–17 in each group.
nnPo0.01 compared with the control group.
#Po0.05.
##Po0.01 compared with the model group.vasoconstriction. A long-term treatment with L-NAME
decreased vascular reactivity to Ang II but signiﬁcantly
increased vascular response to PDBu (Fig. 3). Both valsartan
and fasudil treatment showed some improvement for the
vascular reactivity to Ang II and PDBu, but a signiﬁcant
difference between drug-treated and model groups was only
observed in PDBu-induced constraction (Po0.05). As shown
in Fig. 3, the decreased level of response to PDBu provided by
fasudil therapy was greater than valsartan treatment.
NE (106 M)-induced contractile response in Ca2þ-free
K–H solution (0.2770.03 ) represented 1872% of KCl-induced
contraction, and this response was lowered by L-NAME treat-
ment without a signiﬁcant difference (Fig. 3). Valsartan treat-
ment did not affect this response, whereas fasudil treatment
markedly enhanced the contraction of aortic segments compared
to the L-NAME-evoked hypertensive group.
3.3. Endothelium-dependent and -independent vasorelaxation
Endothelium-dependent relaxation of aortic rings precon-
tracted with NE was shown in Fig. 4A. Exposure to cumula-
tive concentrations of acetylcholine (Ach) led to a marked
vasorelaxation of NE-constricted rings in the control group.
In contrast, the response of aortic rings from the model group
to Ach was almost abolished, indicating an impaired endothe-
lium-dependent relaxation of the aorta in the NO-deﬁcient
rats induced by L-NAME treatment. Little improvement of
this effect was observed in the valsartan-treated group, but a
signiﬁcantly improved vasorelaxation was provided by fasudil
therapy in comparison to the model group (Po0.05).
The vasodilatory function of vascular smooth muscle was
tested by cumulative addition of sodium nitroprusside (SNP)
to the organ bath, and the results showed that there was no
signiﬁcant difference of endothelium-independent dilation in
all groups (Fig. 4B).
3.4. Histopathological change of heart
Standard light microscopy was used to evaluate the development
of cardiac hypertrophy. The NO-deﬁcient rats treated by
L-NAME showed dramatically increased size of cardiomyocytes
compared to the rats in control group (15.6970.43 mm vs.
11.1470.27 mm, respectively, Po0.01). Moreover, disarray of
hypertrophied myocytes with increscent nuclei was observed at
the ventricular walls of the rats in the model group. This
phenomenon was countered by 6-week treatment with valsartan,
but not by fasudil therapy (Fig. 5). The cardiomyocyte diameter oft–body weight ratio (HW/BW) at the end of the experiment.
HW (mg) HW/BW (mg/g)
1170727 2.4470.04
1298726nn 2.6270.05
1158729## 2.3670.04##
1338738nn 2.9070.09nn,#
Figure 2 Cumulative concentration-response curves to NE (A), KCl
(B) and CaCl2 (C) in aortic rings from control (K), model (’),
valsartan-treated (m) and fasudil-treated groups (.). Results are
presented as percentage of the maximal contractile response to
80 mM KCl. Values are mean7SEM, n¼10–14. Po0.05 compared
with the control group, #Po0.05 compared with the model group.
Figure 3 Contractile responses of aortic rings to Ang II
(107 M), PDBu (107 M) and NE (106 M) in Ca2þ-free K–H
solution. Results are presented as percentage of the maximal
contractile response to 80 mM KCl. Values are mean7SEM,
n¼10–14. nPo0.05 compared with the control group, #Po0.05
compared with the model group.
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0.26 mm and 15.1870.36 mm, respectively, the former of which
was signiﬁcant shorter than that of the model group (Po0.01).Microscopic pictures taken of myocardial ﬁbrosis with
Masson’s trichrome stain are shown in Fig.6. The area of
interstitial ﬁbrosis in the model group was signiﬁcantly greater
than that in the control group (Po0.01). Compared to the
model group, myocardial ﬁbrosis was signiﬁcantly less in the
valsartan- and fasudil-treated groups (Po0.01).3.5. Expression of RhoA and ROCK-I in aorta
Analysis with the antibody speciﬁc for RhoA revealed that the
expression of RhoA in aorta was signiﬁcantly increased in the
Figure 4 Cumulative concentration–response curves to Ach (A)
and SNP (B) in aortic rings from control (K), model (’),
valsartan-treated (m) and fasudil-treated groups (.). Values are
mean7SEM, n¼6–14. Po0.05 compared with the control
group, #Po0.05 compared with the model group.
Figure 5 Histopathological changes of cardiomyocytes in differ
photomicrographs of myocytes by HE staining from control (A), m
respectively. (E) Cardiomyocyte diameter for different groups. Value
group, ##Po0.01 compared with the model group.
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There was a signiﬁcant reduction in vascular RhoA expression
in both the valsartan and fasudil treated animals (Po0.05).
Similarly, in the aorta of the model group, a marked
augmentation of ROCK-I expression was observed, which
was well corrected to the basal level by both valsartan and
fasudil treatment (Fig. 7).4. Discussion
The present study has demonstrated the changed arterial
reactivity to various vasoconstrictors and vasodilators due to
chronic blockade of NOS, as well as the beneﬁcial effects of
Rho-kinase inhibitor and Ang II receptor antagonist on the
vascular hyporesponsiveness. To the best of our knowledge,
this is the ﬁrst report of the effects of Rho-kinase inhibitor on
vascular function in the L-NAME-induced hypertensive rat.
Long-term administration of L-NAME caused a sustained
elevation in SBP and a marked decrease in the heart rate of
normotensive rats in our study, in accordance with other
reports3,5,6. Previous data showed that Ang II receptor
antagonist prevented the development of hypertension
induced by L-NAME treatment5. Badejo et al.12 reported that
fasudil caused a dose-dependent decrease in pulmonary and
systemic arterial pressure in normotensive rats. In the present
study, we found that a daily intake of either valsartan or
fasudil (30 mg/kg) restored the increased SBP to close the
normal level in the chronic NO-deﬁcient rats.
Vascular dysfunction is one of the complicated features in
hypertension. A large body of research has shown the abnorm-
ality in vascular reactivity of L-NAME-induced hypertensive rats
to the alpha-adrenergic receptor agonist, Ang II and drugs acting
beyond receptor activation13. Henrion et al.4 observed that
chronic NOS blockade induced a hyporeactivity of the blood
vessel to various stimulus. Further research conﬁrmed that the
hyporesponsiveness of aorta might develop as a result of high-
dose, chronic L-NAME administration13. The present study
found that the cumulative concentration–response to NE wasent groups (a bar indicates 25 mm). (A)–(D), representative
odel (B), valsartan-treated (C) and fasudil-treated (D) groups,
s are mean7SEM, n¼3. Po0.01 compared with the control
Figure 6 Masson’s trichrome staining for heart in different groups (a bar indicates 25 mm). A, control group; B, model group; C,
valsartan-treated group; D, fasudil-treated group; E, ratio of the total area of ﬁbrosis to the total area of the image. Values are
mean7SEM, n¼3. Po0.01 compared with the control group, ##Po0.01 compared with the model group.
Figure 7 Expression of RhoA (left) and ROCK-I (right) in the aortas of L-NAME-treated hypertensive rats. Representative blots were
obtained from Western blotting results. Each bar represents mean7SEM of 4–6 tissue samples per group. Po0.05 and Po0.01
compared with the control group, #Po0.05 and ##Po0.01 compared with the model group.
Bainian Chen et al.456signiﬁcantly decreased in the aorta of NO-deﬁcient rats com-
pared to the control rats. Moreover, the vasoconstriction caused
by KCl, Ang II and by NE in Ca2þ-free medium was also
attenuated in the model group, though not signiﬁcantly. Conse-
quently, the vascular smooth muscle contractile function seemed
globally reduced in response to exogenous vasoconstrictors.
Previously, Henrion and coworkers reported an improved
contractile response to phenylephrine through treatment with
angiotensin I-converting enzyme inhibitor (ACEI) quinapril in
the aortic segments from L-NAME induced hypertensive rats.
Here, we observed that a long-term administration of valsar-
tan reversed the hyporeactivity of aorta to NE and Ang II in
the NO-deﬁcient rats. In contrast with the effect of valsartan
on the vasoconstriction to NE, chronic fasudil treatment
signiﬁcantly improved the contractile response to NE in
Ca2þ-free medium but showed limited beneﬁts on sustained
contraction to NE cumulatively added in K–H solution.
Vascular smooth muscle may constrict physically with rapid
and transient contraction in response to NE in Ca2þ-free
medium, due to the intracellular Ca2þ release fromsarcoplasmic reticulum triggered by inositol 1,4,5-tripho-
sphate14. Previous observations indicate that the RhoA/
ROCK pathway is implicated in the tonic phase of vasocon-
striction with no evident role in the physic response15. The
present ﬁndings thus further conﬁrm the conclusion that
inhibition of Rho-kinase interferes more with the force
maintenance (tonic contraction) rather than the initial phase
of force development (physic contraction).
Interestingly, we observed remarkably enhanced reactivity
of the aorta to the protein kinase C (PKC) activator PDBu in
chronic NOS inhibition rats compared to the control rats. The
results from Bank and colleagues’ research on the mechanism
of vasoconstriction induced by long-term inhibition of NOS in
rats indicate that the decreased production of NO resets the
intrinsic vascular smooth muscle tone, which may be mediated
by an increase in intracellular Ca2þ concentration or sensitiv-
ity16. Further study shows that NOS inhibition activates the
L- and T-type Ca2þ channels in arterioles17. Additionally, the
Ca2þ inﬂux through T-type Ca2þ channels in arterial rings is
reported to increase in the L-NAME induced hypertension5.
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group might result from an excessive activation of Ca2þ
channels. Both drug treatments decreased this hyperactivity,
with a more pronounced reduction obtained in the fasudil-
treated group, which may be ascribed to the important
regulatory role of Rho-kinase in T-type Ca2þ channels18.
Endothelium-dependent relaxative response to Ach was mark-
edly blunted in the aorta of L-NAME induced hypertensive rats
compared to the control ones in the present study and other
similar experiment4,5. This endothelial dysfunction might result
from a decreased production of NO and an increased release of
vasoconstrictors in endothelial cells due to long-term inhibition of
NOS19. In this work, the endothelium-dependent vasorelaxation
was signiﬁcantly augmented in the rats treated with fasudil,
evidenced by a dramatically increased response to Ach in the
fasudil-treated group in comparison to that of the model group. It
has been reported that Ach fails to dilate the preconstricted aorta
in quinapril-treated NO-deﬁcient rats, implying that the antihy-
pertensive drug such as ACEI may not enhance the endothelium-
dependent vasorelaxation4. Similarly, we found that the cumula-
tive concentration–response to Ach was slightly improved by
valsartan therapy. These results suggested that the beneﬁcial effect
of Rho-kinase inhibition on endothelial function might be better
than that of AT1 receptor blockade. As the endothelium-intact
aorta was studied in this experiment, the endothelium-denuded
aorta should be used in further experiments in order to enhance
the direct understanding of differential reactions between fasudil
and valsartan on endothelial cells.
Western blotting results from RhoA/ROCK pathway in aorta
gave more favorable substantiation to the alteration of vascular
function and the beneﬁcial effects of both valsartan and fasudil in
the NO-deﬁciency rats. RhoA, one of the small GTP binding
proteins, is known to govern a wide range of cellular functions
through its downstream effector ROCK. RhoA/ROCK signaling
pathway has been implicated in the inhibition of myosin phos-
phatase, accumulation of phosphorylated myosin light chain as
well as the regulation of Ca2þ sensitivity and formation of stress
ﬁbers in vascular smooth muscle cells8,9. Because of the key role of
RhoA and its effector ROCK in the contraction and proliferation
of smooth muscle cells and the permeability of endothelial cells,
this molecular pathway is now extensively accepted as an
important target in various cardiovascular diseases, especially
hypertension9. Recent ﬁndings have revealed an increased con-
tribution of the RhoA/ROCK pathway to the basal and patho-
logical tone of vasculature in different experimental hypertension
animals, including chronic L-NAME treated rats20, spontaneously
hypertensive rats (SHRs)20,21 and Ang II-induced hypertensive
rats22. Additionally, the activation of RhoA/ROCK pathway is
referred as a common molecular switch in downstream signaling
and a pivotal component of hypertension23. In the present study,
the expression of RhoA in aorta was signiﬁcantly increased in the
L-NAME-induced hypertensive rats compared to that of the
control group, consistent with results of other work20. Moreover,
the level of ROCK expression in the vascular tissues of the model
group was much higher than that of control group, which
indicated that the RhoA/ROCK signaling pathway was dramati-
cally enhanced due to long-term NOS inhibition. Previous reports
document that valsartan diminishes the expression level of
membranous RhoA24 and reduces the RhoA activation in
SHRs25. Our results showed that the expressions of both RhoA
and ROCK in the aortas of NO-deﬁcient rats were signiﬁcantly
decreased by valsartan administration compared to those ofcontrol rats, further supporting the point that the antihypertensive
effect of AT1 receptor blocker may be mediated through the
deactivation of RhoA/ROCK pathway. The data of the present
study for the ﬁrst time revealed that fasudil signiﬁcantly decreased
the expressions of RhoA and ROCK-I in the aortas of chronic
NO-deﬁciency hypertensive rats. Combining with the earlier
ﬁndings that endothelium-dependent dilation was markedly
enhanced by Rho-kinase inhibition26, it may give rise to the
speculation that the hypotensive effect of fasudil is attributed to
the improvement of endothelial dysfunction through a reduction
in the activated RhoA/ROCK signaling pathway in the vascu-
lature of hypertensive animals.
Apart from the attenuated vascular reactivity, the cardiac
hypertrophy in the model group was also observed in the
present study. Cardiac hypertrophy represents a remodeling
process of heart due to diverse pathological stimuli27, and
previous reports have demonstrated that persistent hyperten-
sion induced by chronic L-NAME treatment results in hyper-
trophied hearts in rats5,28.
Consistent with the ﬁnding that Ang II receptor antagonism
ameliorates cardiac hypertrophy5, the present study showed
that administration of valsartan signiﬁcantly reduced the heart
weight and heart weight–body weight ratio, and markedly
decreased the cardiomyocyte diameter and myocardial ﬁbro-
sis. However, administration of fasudil signiﬁcantly increases
the left ventricle weight and left ventricle weight–body weight
ratio in the L-NMAE-treated SHRs29. Recently, studies on
transgenic animal models illustrate that cardiac-speciﬁc over-
expression of RhoA does not cause ventricular hypertrophy30
and haploinsufﬁciency of the ROCK1 gene fails to prevent the
development of cardiac hypertrophy in response to Ang II or
L-NAME31, which suggests that the RhoA/ROCK pathway is
not responsible for the development of cardiac hypertrophy.
The results from the present study showed that fasudil therapy
failed to reverse the increased heart index and the enlarged
cardiomyocyte diameter, whereas fasudil treatment signiﬁ-
cantly decreased the area of myocardial ﬁbrosis.
Accumulating evidence suggests that Rho/Rho-kinase pathway
is substantially involved in the pathogenesis of various cardiovas-
cular diseases8,9. Rho-kinase inhibitors are currently being devel-
oped as the next generation of therapeutic agents, with high
potency and low side effect on heart rate, for certain cardiovas-
cular pathological conditions, especially hypertension32,33. Fasudil,
a selective Rho-kinase inhibitor, has been widely used for
prevention and treatment of cerebral vasospasm after subarach-
noid hemorrhage and pulmonary artery hypertension since a
decade ago8. Our data demonstrate that fasudil shows antihyper-
tensive effect on the long-term NO-deﬁcient rats and beneﬁcial
effect on the endothelium-dependent vasorelaxation, whereas
chronic fasudil treatment leads to a marked elevation in the heart
rate. Therefore, fasudil therapy for the patients with compromised
cardiac function should be pursued with caution at the clinical
situation due to this unwanted adverse event.
In conclusion, these results suggest that chronic NOS
inhibition not only induces high blood pressure and cardiac
hypertrophy, but also impairs the vascular function. Both Ang
II receptor antagonism and Rho-kinase inhibition exhibit an
antihypertensive effect, while only Ang II receptor antagonist
shows antihypertrophic potential on cardiomyocytes. The AT1
receptor blocker improves the attenuated vasoconstriction,
whereas the Rho-kinase inhibitor exerts greater beneﬁcial
effect on endothelium-dependent vasorelaxation than the
Bainian Chen et al.458AT1 receptor blocker. Our work provides the ﬁrst evidence
that both valsartan and fasudil decrease the augmented RhoA/
ROCK signaling pathway in the vasculature of hypertensive
rat, which may be one of the molecular mechanisms for their
blood pressure-lowering activity.Acknowledgments
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